ONCOLife presents an exclusive interview with John Santini, CEO of Vergent Bioscience. In this session, we explore how intraoperative molecular imaging with abenacianine for injection (VGT-309) is ...

ONCOLife presents an exclusive interview with Dr. John Gribben, Professor at the Cancer Institute in London. In this session, ...

ONCOLife presents an exclusive interview with Lorna Warwick, CEO of Lymphoma Coalition. In this session, we explore the critical role of patient advocacy in improving access to CAR T-cell therapy — a ...

The FDA has approved ' investigational drug, ZW171, for clinical trials. This novel bispecific antibody targets mesothelin-expressing cancers, such as ovarian and non-small cell lung cancer.

With FDA Fast Track designation, the new non-opioid pain medication SRP-001 shows promising Phase 1 trial results, offering a safer alternative for pain management.

Bristol Myers Squibb has announced successful outcomes from the KRYSTAL-12 Phase 3 trial. KRAZATI (adagrasib), targeting non-small cell lung cancer.

ONCOLife presents an exclusive interview with Nick Slack, Chairman and CEO of The START Center for Cancer Research. In this session, we explore how the integration of the Carolina Urologic Research ...

We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the future of breast cancer screening and the role of artificial intelligence ...

ONCOLife presents an exclusive interview with Dr. Miguel-Angel Perales, Co-Chair of the CAR T Vision initiative, as he shares his expert insights on the major barriers preventing eligible patients ...

The START Center for Cancer Research dosed the first patient in Moderna’s Phase 1 trial of mRNA-4106, a multivalent mRNA-based cancer vaccine targeting advanced solid tumors.